Use your browser's back button to choose another title or click here for a New Search.



How to Get the Article

 Email CTN Library (free)

PubMed Central (free)

Journal subscriber access

 

 Comments?

 

Bookmark and Share

 

 

 

Predictors of Treatment Response in Adolescents with Comorbid Substance Use Disorder and Attention/Deficit-Hyperactivity Disorder.

Journal of Substance Abuse Treatment 2012;44(2):224-230. [doi: 10.1016/j.jsat.2012.07.001]

Leanne Tamm, PhD (University of Texas Southwestern Medical Center, TX Node), Kathlene Trello-Rishel, PhD (Mental Health and Mental Retardation of Tarrant County, TX Node), Paula D. Riggs, MD (University of Colorado, FNA Node), Paul A. Nakonezny, PhD (University of Texas Southwestern Medical Center, TX Node), Michelle C. Acosta, PhD (National Development and Research Institutes, Inc., GNY Node), Genie L. Bailey, MD (Stanley Street Treatment and Resources, Inc., NEC Node), Theresa M. Winhusen, PhD (University of Cincinnati/CinARC, OV Node).

Attention-Deficit/Hyperactivity Disorder (ADHD) frequently co-occurs with substance use disorder (SUD) and is associated with poor substance-use treatment outcomes. A National Drug Abuse Treatment Clinical Trials Network study (CTN-0028) evaluating osmotic-release oral system methylphenidate (OROS-MPH) for adolescents with ADHD and SUD, concurrently receiving behavioral therapy, revealed inconsistent medication effects on ADHD or SUD. Clinical care for this population would be advanced by knowledge of treatment outcome predictors. Data from the randomized placebo-controlled trial (n=299) were analyzed. Significant treatment predictors included: 1) Substance use severity, associated with poorer ADHD and SUC outcomes, 2) ADHD severity, associated with better ADHD and SUD outcomes, 3) comorbid conduct disorder, associated with poorer ADHD outcomes, and 4) court-mandated status, associated with better SUD outcomes by poorer treatment completion. An interaction effect showed that OROS-MPH improved SUD outcomes in adolescents with comorbid conduct disorder compared to placebo.

Conclusions: Individuals with ADHD and SUD who are also diagnosed with conduct disorder could benefit from concurrent treatment with OROS-MPH in addition to treatment for SUD. The study also found that individuals with more severe ADHD but less severe SUD showed better treatment outcomes. With regards to mandating treatment, better SUD outcomes were found in adolescents court-mandated to receive treatment, but there were also lower treatment completion rates in the court-mandated group. Thus, particular focus on treatment retention efforts might be important for this group in order to achieve better SUD outcomes. (Article (Peer-Reviewed), PDF, English, 2012)

Keywords: Adolescents | Attention Deficit Hyperactivity Disorder (ADHD) | Community health services | Concerta | Co-occurring disorders | CTN platform/ancillary study | Osmotic-Release Methylphenidate (OROS-MPH) | Journal of the American Academy of Child & Adolescent Psychiatry (journal)

Document No: 851, PMCID: 22889694, PMCID: PMC3499678.

Submitted by the Leanne Tamm, PhD, Tx Node, 8/20/2012.

AUTHORS SEARCH LINK
Acosta, Michelle C. search
Bailey, Genie L. search mail
Nakonezny, Paul A. search
Riggs, Paula D. search mail
Tamm, Leanne search mail
Trello-Rishel, Kathlene search mail
Winhusen, Theresa M. search mail
PROTOCOLS
NIDA-CTN-0028 search www
PARTICIPATING NODES
Ohio Valley (Lead) search www
Appalachian Tri-State search www
Delaware Valley search www
Florida Node Alliance search www
Greater New York search www
Mid-Atlantic search www
New England Consortium search www
Southern Consortium search www
Texas search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 12/2012 -- http://ctndisseminationlibrary.org/display/851.htm
info@ctndisseminationlibrary.org